title: Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
abstract: The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS). Thirty-seven patients with PCOS were randomly assigned to receive spironolactone 100 mg/d (spironolactone group, 18 patients) or spironolactone 100 mg/d plus metformin 2000 mg/d (combination group, 19 patients) for 12 months. BMI, modified Ferriman-Gallway score (FGS), serum levels of regarding hormones, and homeostasis model assessment of insulin resistance (HOMA-IR) index were assessed before and after the treatments. Six patients in the spironolactone group and four patients in the combination group reported inter-menstrual vaginal bleeding during treatments. In hirsutism scores, the spironolactone therapy resulted in 25.2% reduction, while combination therapy resulted in 28.3% reduction (p > 0.05, between groups). When the groups were compared in terms of percent changes in BMI, FGS, HOMA-IR, and hormone values other than free testosterone, no significant difference was noted. In the present study, FGSs were significantly decreased in both groups; however, combination therapy was not more effective than spironolactone alone in terms of BMI, FGS, hormone levels, or insulin resistance.
authors.affiliation: a Division of Endocrinology and.
authors.forename: Halit
authors.initials: H
authors.lastname: Diri
authors.affiliation: a Division of Endocrinology and.
authors.forename: Sulbiye
authors.initials: S
authors.lastname: Karaburgu
authors.affiliation: b Department of Internal Diseases , Erciyes University Medical School , Kayseri , Turkey.
authors.forename: Banu
authors.initials: B
authors.lastname: Acmaz
authors.affiliation: a Division of Endocrinology and.
authors.forename: Kursad
authors.initials: K
authors.lastname: Unluhizarci
authors.affiliation: a Division of Endocrinology and.
authors.forename: Fatih
authors.initials: F
authors.lastname: Tanriverdi
authors.affiliation: a Division of Endocrinology and.
authors.forename: Zuleyha
authors.initials: Z
authors.lastname: Karaca
authors.affiliation: a Division of Endocrinology and.
authors.forename: Fahrettin
authors.initials: F
authors.lastname: Kelestimur
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D007986:Luteinizing Hormone / Q000097:blood; D008687:Metformin / Q000627:therapeutic use*; D008796:Metrorrhagia / Q000139:chemically induced; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D009839:Oligomenorrhea / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000451:Mineralocorticoid Receptor Antagonists; D012738:Sex Hormone-Binding Globulin; D013148:Spironolactone; D013739:Testosterone; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008687:Metformin; D006854:Hydrocortisone
keywords: Metformin; PCOS; spironolactone; treatment